Notably, XO activity is associated with obesity-related metabolic dysfunction, and XO inhibitors typically prescribed for gout or hyperuricemia are proving to be effective in mitigating cardiovascular and renal complications of diabetes (504, 507, 508). This evidence concerns the gene XDH and Obesity.